Drug Overview

NY-ESO-1 GLA-SE vaccine ID-G305 (also known as ID-G305) is an investigational, recombinant protein-based cancer vaccine designed to target and eliminate tumors that express the NY-ESO-1 antigen. This vaccine consists of a full-length, purified recombinant NY-ESO-1 protein combined with a potent, synthetic immune-stimulating adjuvant called GLA-SE (Glucopyranosyl Lipid A in a Stable Emulsion).

In the clinical landscape of March 2026, NY-ESO-1 GLA-SE is recognized as a leading candidate in the “Cancer-Testis (CT) Antigen” vaccination field. NY-ESO-1 is a protein normally only found in the testes or developing fetuses, where it is protected from the immune system. However, it is “re-expressed” in many aggressive cancers, including melanoma, sarcoma, and ovarian cancer. Because it is not found in healthy adult tissues, the ID-G305 vaccine can “train” the immune system to recognize NY-ESO-1 as a foreign invader and attack the tumor without causing significant damage to the rest of the body.

Generic Name: NY-ESO-1 GLA-SE vaccine ID-G305.
Code Name: ID-G305.
Drug Class: Cancer Vaccine; Immunotherapy; Recombinant Protein Vaccine.
Mechanism: Active immunization against the NY-ESO-1 antigen, boosted by a TLR4 agonist (GLA-SE).
Route of Administration: Intradermal (ID) or Intramuscular (IM) injection.
FDA Approval Status: Investigational. As of March 2026, ID-G305 is not FDA-approved. It has been evaluated in multiple Phase 1 and Phase 2 trials, both as a single agent and in combination with other immunotherapies (like pembrolizumab or GVAX).

What Is It and How Does It Work? (Mechanism of Action)

The ID-G305 vaccine works by using a “two-part” strategy to provoke a massive and specific immune response against the cancer.

1. The Target: NY-ESO-1 Protein

NY-ESO-1 is a highly “immunogenic” protein, meaning the immune system is naturally inclined to notice it.

Selective Targeting: By using the full-length protein, the vaccine provides a wide range of “targets” (epitopes) that can be recognized by both CD4+ (helper) and CD8+ (killer) T-cells.
Tumor Specificity: Because NY-ESO-1 is rarely found in healthy cells, the vaccine-induced T-cells ignore normal tissue and home in specifically on the malignant cells.

2. The Booster: GLA-SE Adjuvant

Peptides and proteins alone are often not enough to wake up the immune system. GLA-SE is a synthetic version of a bacterial molecule.

TLR4 Activation: It binds to Toll-like receptor 4 (TLR4) on the surface of dendritic cells (the “sentinels” of the immune system).
Cytokine Storm (Localized): This binding triggers the release of pro-inflammatory cytokines, which tells the immune system that there is a “dangerous infection” at the site of the injection.
Antigen Presentation: Dendritic cells “swallow” the NY-ESO-1 protein, process it, and present it to T-cells in the lymph nodes, creating a specialized “army” of cancer-fighting cells.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for NY-ESO-1 GLA-SE vaccine ID-G305.

Clinical research through 2026 has primarily focused on the following “NY-ESO-1 positive” cancers:

Soft Tissue Sarcoma: Particularly Synovial Sarcoma and Myxoid/Round Cell Liposarcoma, which have some of the highest rates of NY-ESO-1 expression (over 80%).
Ovarian Cancer: Evaluated as a maintenance therapy to prevent recurrence in patients who are in remission.
Advanced Melanoma: Studied in combination with checkpoint inhibitors to overcome resistance.
Multiple Myeloma: Investigated for its ability to clear out “minimal residual disease” after a stem cell transplant.

Dosage and Administration Protocols

As an investigational drug, ID-G305 dosing is strictly managed within clinical trials (such as the NCT02387125 or NCT02737787 studies).

Treatment Parameter	Investigational Specification (2025–2026)
Route	Intradermal (ID) or Intramuscular (IM) injection.
Dosing Schedule	Typically administered once every 3 or 4 weeks for a total of 4 to 6 doses.
Standard Dose	Often consists of 250 µg of NY-ESO-1 protein mixed with 5 µg of GLA-SE.
Booster Doses	May be given every 3 to 6 months to maintain immune memory.
Sequence	Often administered alongside or shortly after other immunotherapies (like GVAX or PD-1 inhibitors).

Clinical Efficacy and Research Results

As of early 2026, results from Phase 1b and Phase 2 trials have provided significant biological proof-of-concept:

Immune Conversion: In trials for sarcoma and ovarian cancer, over 90% of patients developed a measurable T-cell or antibody response to NY-ESO-1 after receiving the ID-G305 vaccine.
Synergy with Checkpoint Inhibitors: Data from 2025 showed that adding ID-G305 to pembrolizumab led to better tumor shrinkage in NY-ESO-1 positive melanoma than pembrolizumab alone.
Durable Stability: Several patients with advanced synovial sarcoma achieved “stable disease” that lasted for over 18 months, which is significant for this aggressive cancer.
Intratumoral T-cells: Biopsies taken after vaccination have confirmed a significant increase in the number of killer T-cells inside the tumor, proving the vaccine is successfully “trafficking” the immune system to the cancer.

Safety Profile and Side Effects

The safety profile of ID-G305 is generally very favorable, as the vaccine is highly targeted.

Common Side Effects (>50%):

Injection Site Reactions: Redness (erythema), swelling, and tenderness at the site of the shot. This is a positive sign that the adjuvant is working.
Flu-like Symptoms: Mild fever, chills, and muscle aches for 24–48 hours after the injection.
Fatigue: General systemic tiredness, manageable with rest.

Serious Risks:

Anaphylaxis: Rare risk of a severe allergic reaction to the protein or adjuvant.
Autoimmunity: A theoretical risk that the immune system could attack healthy tissues, though NY-ESO-1’s limited expression in adults makes this risk much lower than with other immunotherapies.
Induration: A small, hard lump at the injection site that may take several weeks to resolve.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, ID-G305 is being used to study “Immune Surveillance of Cancer Stem Cells.” Researchers are investigating if they can target NY-ESO-1 on the surface of “quiescent” (sleeping) cancer stem cells to prevent a relapse years later. In 2026, there is also intense focus on “RNA-Loaded Adjuvants.” Scientists are exploring whether adding mRNA instructions to the ID-G305 platform can create an even stronger “double-boost” for the immune system. Furthermore, studies are exploring “Multivalent Vaccines,” where ID-G305 is combined with other antigens (like MAGE-A3) to create a broader attack on the tumor.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

Antigen Testing: Mandatory biopsy or blood test to confirm the tumor is NY-ESO-1 positive.
Baseline Immune Panel: To establish the starting state of the patient’s T-cell populations.

“Do’s and Don’ts” List:

DO expect a “local reaction” at the injection site; keeping the area clean and avoiding tight clothing can help with comfort.
DO report any “systemic” symptoms like a high fever or severe shortness of breath immediately to your oncology team.
DON’T receive any live-virus vaccines (like shingles or MMR) during the active vaccination phase without consulting your doctor.
DON’T take high-dose steroids (like Prednisone) unless directed, as they can “dampen” the very immune response the vaccine is trying to create.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. NY-ESO-1 GLA-SE vaccine ID-G305 is an investigational agent and is not approved by the U.S. FDA. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.